Role of HIV Infection Duration and CD4 Cell Level at Initiation of Combination Anti-Retroviral Therapy on Risk of Failure

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Lodi, Sara ^a,b   Phillips, Andrew ^a   Fidler, Sarah ^c   Hawkins, David ^d   Gilson, Richard ^e   McLean, Ken ^f   Fisher, Martin ^g   Post, F ^ax   Johnson, Anne M ^a   Walker Nthenda, Louise ^a   Dunn, David ^a   Porter, Kholoud ^a   Kennedy, N ⁱ   Pritchard, J ^j   Andrady, U ^k   Rajda, N ^l   Donnelly, C ^m   McKernan, S ^m   Drake, S ⁿ   Gilleran, G ⁿ   White, D ⁿ   Ross, J ^o   Harding, J ^o   Faville, R ^o   Sweeney, J ^p   Flegg, P ^p   Toomer, S ^p   Wilding, H ^q   Woodward, R ^q   Dean, G ^r   Richardson, C ^r   Perry, N ^r   Gompels, M ^s   Jennings, L ^s   Bansaal, D ^t   Browing, M ^u   Connolly, L ^u   Stanley, B ^v   Estreich, S ^w   Magdy, A ^w   O'Mahony, C ^x   Fraser, P ^y   Jebakumar, S P R ^z   David, L ^aa   Mette, R ^ab   Summerfield, H ^ac   Evans, M ^ad   White, C ^ae   Robertson, R ^af   Lean, C ^ag   Morris, S ^ag   Winter, A ^ah   Faulkner, S ^ai   Goorney, B ^aj   Howard, L ^ak   Fairley, I ^al,ca   Stemp, C ^al   Short, L ^am   Gomez, M ^an   Young, F ^an   Roberts, M ^ao,bx   Green, S ^ao   Sivakumar, K ^ap   Minton, J ^aq,ar   Siminoni, A ^aq   Calderwood, J ^ar   Greenhough, D ^ar   DeSouza, C ^as   Muthern, Lisa ^as   Orkin, C ^as   Murphy, S ^at   Truvedi, M ^at   McLean, K ^f   Hawkins, D ^d   Higgs, C ^d   Moyes, A ^d   Antonucci, S ^o   McCormack, S ^o   Lynn, W ^au   Bevan, M ^av   Fox, J ^av   Teague, A ^av   Anderson, J ^aw   Mguni, S ^aw   Campbell, L ^ax   Mazhude, C ^ay   Russell, H ^ay   Gilson, R ^a   Carrick, G ^a   Ainsworth, J ^az   Waters, A ^az   Byrne, P ^ba   Johnson, M ^ba   Fidler, S ^bb   Kuldanek, K ^bb   Mullaney, S ^bb   Lawlor, V ^bc   Melville, R ^bc   Sukthankar, A ^bd   Thorpe, S ^bd   Murphy, C ^be   Wilkins, E ^be   Ahmad, S ^bf   Green, P ^bf   Tayal, S ^bg   Ong, E ^bh   Meaden, J ^bi   Riddell, L ^bj   Loay, D ^bk   Peacock, K ^bk   Blackman, H ^bl   Harindra, V ^bl   Saeed, A M ^bm   Allen, S ^bn   Natarajan, U ^bn   Williams, O ^bo,by   Lacey, H ^o   Care, C ^bp   Bowman, C ^bp   Herman, S ^bp   Devendra, S V ^bq   Wither, J ^bq   Bridgwood, A ^br   Singh, G ^br   Bushby, S ^bs   Kellock, D ^o   Young, S ^o   Rooney, G ^bt   Snart, B ^bt   Currie, J ^bu   Fitzgerald, M ^bu   Arumainayyagam, J ^bv   Chandramani, S ^bv   Rajamanoharan, S ^bw   Robinson, T ^bw   Taylor, B ^bz   Brewer, C ^ca   more..

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^d CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^f CHARING CROSS HOSPITAL   (United Kingdom)

^g Worthing Hospital   (United Kingdom)

^h KING'S COLLEGE LONDON   (United Kingdom)

ⁱ MONKLANDS HOSPITAL   (United Kingdom)

^j Ashford Hospital   (United Kingdom)

^k YSBYTY GWYNEDD   (United Kingdom)

^l NORTH HAMPSHIRE HOSPITAL   (United Kingdom)

^m ROYAL VICTORIA HOSPITAL   (United Kingdom)

ⁿ BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^o Birmingham Heartlands Hospital ^*  (United Kingdom)

^p BLACKPOOL VICTORIA HOSPITAL   (United Kingdom)

^q ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

^r ROYAL SUSSEX COUNTY HOSPITAL   (United Kingdom)

^s SOUTHMEAD HOSPITAL   (United Kingdom)

^t QUEEN S HOSPITAL   (United Kingdom)

^u Cardiff Royal Infirmary   (United Kingdom)

^v Lillyhall Business Centre   (United Kingdom)

^w ST HELIER HOSPITAL   (United Kingdom)

^x St Helier Hospital ^*  (United Kingdom)

^y CHESTERFIELD ROYAL HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^z ESSEX COUNTY HOSPITAL   (United Kingdom)

^aa Essex County Hospital ^*  (United Kingdom)

^ab MAYDAY UNIVERSITY HOSPITAL   (United Kingdom)

^ac Weymouth and District Hospital   (United Kingdom)

^ad NINEWELLS HOSPITAL   (United Kingdom)

^ae UNIVERSITY HOSPITAL OF NORTH DURHAM   (United Kingdom)

^af Muirhouse Medical Group   (United Kingdom)

^ag WESTERN GENERAL HOSPITAL   (United Kingdom)

^ah GLASGOW ROYAL INFIRMARY   (United Kingdom)

^ai GLOUCESTERSHIRE ROYAL HOSPITAL   (United Kingdom)

^aj HOPE HOSPITAL   (United Kingdom)

^ak Hospital   (United Kingdom)

^al Harrogate and District Foundation Trust Hospital   (United Kingdom)

^am HUDDERSFIELD ROYAL INFIRMARY   (United Kingdom)

^an ST MARY S HOSPITAL   (United Kingdom)

^ao Kidderminster District General Hospital   (United Kingdom)

^ap QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^aq LEEDS GENERAL INFIRMARY   (United Kingdom)

^ar ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^as BARTS HEALTH NHS TRUST   (United Kingdom)

^at CENTRAL MIDDLESEX HOSPITAL   (United Kingdom)

^au EALING HOSPITAL   (United Kingdom)

^av GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^aw HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

^ax KING S COLLEGE HOSPITAL   (United Kingdom)

^ay UNIVERSITY HOSPITAL LEWISHAM   (United Kingdom)

^az NORTH MIDDLESEX UNIVERSITY HOSPITAL   (United Kingdom)

^ba ROYAL FREE HOSPITAL   (United Kingdom)

^bb ST MARY S HOSPITAL   (United Kingdom)

^bc WHIPPS CROSS UNIVERSITY HOSPITAL   (United Kingdom)

^bd MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^be NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

^bf WITHINGTON HOSPITAL   (United Kingdom)

^bg JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

^bh NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

^bi NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^bj NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^bk GEORGE ELIOT HOSPITAL   (United Kingdom)

^bl ST MARY S HOSPITAL   (United Kingdom)

^bm ROYAL PRESTON HOSPITAL   (United Kingdom)

^bn EAST SURREY HOSPITAL   (United Kingdom)

^bo GLAN CLWYD HOSPITAL   (United Kingdom)

^bp ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^bq ROYAL SHREWSBURY HOSPITAL   (United Kingdom)

^br UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

^bs SUNDERLAND ROYAL HOSPITAL   (United Kingdom)

^bt GREAT WESTERN HOSPITAL   (United Kingdom)

^bu TAUNTON AND SOMERSET HOSPITAL   (United Kingdom)

^bv MANOR HOSPITAL   (United Kingdom)

^bw WATFORD GENERAL HOSPITAL   (United Kingdom)

^bx WORCESTERSHIRE ROYAL HOSPITAL   (United Kingdom)

^by WREXHAM MAELOR HOSPITAL   (United Kingdom)

^bz WYCOMBE HOSPITAL   (United Kingdom)

^ca YORK HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NUCLEOTIDE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADOLESCENT; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; DISEASE DURATION; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; RISK ASSESSMENT; SEROCONVERSION; SURVIVAL; VIROLOGY;

ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; MALE; RISK; TREATMENT FAILURE;

EID: 84884549767     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0075608     Document Type: Article

References (30)

1. World Health Organization (WHO). Antiretroviral therapy for HIV infection in adults and adolescents; -- (2010) revision. Available: http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf. Accessed 18 April 2012.
2. European AIDS, Clinical Society (November(2012) Clinic management and treatment of HIV infected adults in Europe. Available: http://www.europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/EACSGuidelines-v6.1-English-Nov2012.pdf. Accessed 05 December 2012.
3. British, (2012) HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med; 13(S2):: 1-85.
4. Panel on Antiretroviral Guidelines for Adults and Adolescents (2012). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. March: Department of Health and Human Services. p. pp. 1. pp.-239. Available: http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf. Accessed 18 April 2012.
5. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG, (2009) Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 373: 48-57. doi:10.1016/S0140-6736(08)61697-9. PubMed: 19038438.
6. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, et al. (2011) Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 365: 493-505. doi:10.1056/NEJMoa1105243. PubMed: 21767103.
7. Jain V, Kwarisiima D, Liegler T, Clark T, Chamie G, et al. Changes in population-level HIV RNA distribution one year after implementation of key components of an HIV 'test and treat' strategy in rural Uganda. 19th International Conference on AIDS, abstract TULBE04, Washington DC (July(2012).
8. Uy J, Armon C, Buchacz K, Wood K, Brooks JT,; HOPS Investigators (2009) Initiation of HAART at higher CD4 cell counts is associated with a lower frequency of antiretroviral drug resistance mutations at virologic failure. J Acquir Immune Defic Syndr 51:450-3.
9. Harrigan, PRUK Collaborative Group on HIV Drug Resistance; UK CHIC Study Group (2010) Long-term probability of detecting drug-resistant HIV in treatment-naive patients initiating combination antiretroviral therapy. Clin Infect Dis 50: 1286-1287. doi:10.1086/651685. PubMed: 20353363.
10. Harrigan PR, Hogg RS, Dong WW, Yip B, Wynhoven B, et al. (2005) Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis 191: 339-347. doi:10.1086/427192. PubMed: 15633092.
11. UK register of HIV seroconverters (UKRHS) Steering Committee (1996) The UK register of HIV seroconverters: methods and analytical issues. Epidemiol Infect. 117:305-12.
12. Royston P, Ambler G, Sauerbrei W, (1999) The use of fractional polynomials to model continuous risk variables in epidemiology. Int J Epidemiol 28: 964-974. doi:10.1093/ije/28.5.964. PubMed: 10597998.
13. Pillay D, Green H, Matthias R, Dunn D, Phillips A, et al. (2005) Estimating HIV-1 drug resistance in antiretroviral-treated individuals in the United Kingdom. J Infect Dis 192: 967-973. doi:10.1086/432763. PubMed: 16107948.
14. Stanford University (February(2011) HIV drug resistance database. Accessed online 22. http://hivdb.stanford.edu/.
15. von Wyl V, Yerly S, Böni J, Shah C, Cellerai C, et al. (2012) Incidence of HIV-1 Drug Resistance Among Antiretroviral Treatment-Naive Individuals Starting Modern Therapy Combinations. Clin Infect Dis 54: 131-140. doi:10.1093/cid/cir728. PubMed: 22057700.
16. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren J, Neaton JD, Gordin F, Abrams D, Arduino RC, Babiker A, Burman W, Clumeck N, Cohen CJ, Cohn D, Cooper D, Darbyshire J, Emery S, Fätkenheuer G, Gazzard B, Grund B, Hoy J, Klingman K, Losso M, Markowitz N, Neuhaus J, Phillips A, Rappoport CStrategies for Management of Antiretroviral Therapy (SMART) Study Group. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F,et al (2006) CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 355: 2283-2296. doi:10.1056/NEJMoa062360. PubMed: 17135583.
17. SPARTAC Trials Investigators (2013) Short-course antiretroviral therapy in primary HIV infection. N Engl J Me 368:207-217.
18. Miettinen OS, (1983) The need for randomization in the study of intended effects. Stat Med 2: 267-271. doi:10.1002/sim.4780020222. PubMed: 6648141.
19. Clements M, Law M, Pedersen C, Kaldor J, CASCADE Collaboration (2003) Estimating the effect of antiretroviral treatment during HIV seroconversion: impact of confounding in observational data. ME: HIV 4:332-337.
20. Babiker AG, Emery S, Fätkenheuer G, Gordin FM, Grund B, et al. (2012) Considerations in the rationale, design and methods of the Strategic Timing of Antiretroviral Treatment (START) study. Clin Trials 0: 1-32. PubMed: 22547421.
21. Phillips AN, Dunn D, Sabin C, Pozniak A, Matthias R, Geretti AM, Clarke J, Churchill D, Williams I, Hill T, Green H, Porter K, Scullard G, Johnson M, Easterbrook P, Gilson R, Fisher M, Loveday C, Gazzard B, Pillay D, UK Collaborative Group on HIV Drug Resistance, UK CHIC Study GroupUK Collaborative Group on HIV Drug Resistance; UK CHIC Study Group (2005) Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine practice. AIDS 19: 487-494 doi:10.1097/01.aids.0000162337.58557.3d. PubMed: 15764854.
22. Audelin AM, Lohse N, Obel N, Gerstoft J, Jørgensen LB, (2009) The incidence rate of HIV type-1 drug resistance in patients on antiretroviral therapy: a nationwide population-based Danish cohort study 1999-2005. Antivir Ther 14: 995-1000. doi:10.3851/IMP1412. PubMed: 19918103.
23. Bannister WP, Cozzi-Lepri A, Kjaer J, Bonaventura C, Lazzarin A, et al. (2011) Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy. J Antimicrob Chemother 66: 901-911. doi:10.1093/jac/dkr006. PubMed: 21393179.
24. Paredes R, Mocroft A, Kirk O, Lazzarin A, Barton SE, et al. (2000) Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Arch Intern Med 160: 1123-1132. doi:10.1001/archinte.160.8.1123. PubMed: 10789605.
25. Parienti JJ, Massari V, Descamps D, Vabret A, Bouvet E, et al. (2004) Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy. Clin Infect Dis 38: 1311-1316. doi:10.1086/383572. PubMed: 15127346.
26. Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, et al. (2008) Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 358: 2095-2106. doi:10.1056/NEJMoa074609. PubMed: 18480202.
27. Gupta R, Hill A, Sawyer AW, Pillay D, (2008) Emergence of drug resistance in HIV type 1-infected patient safer receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials. Clin Infect Dis 47: 712-722. doi:10.1086/590943. PubMed: 18662137.
28. British, HIV Association UK National Guidelines for HIV Testing 2008. Available: http://www.bhiva.org/documents/Guidelines/Testing/GlinesHIVTest08.pdf. Accessed 04 June 2013.
29. Health Protection Agency (November(2012) HIV in the United Kingdom: 2012 Report. London: Health Protection Services, Colindale. Available: http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317137200016. Accessed 04 June 2013.
30. Lodi S, Phillips A, Touloumi G, Pantazis, Bucher HC, et al. (2010) CD4 decline in seroconverter and seroprevalent individuals in the precombination of antiretroviral therapy era. AIDS 24: 2697-2704. doi:10.1097/QAD.0b013e32833ef6c4. PubMed: 20885283.